Literature DB >> 20181694

Cyclosporine blocks incorporation of HIV-1 envelope glycoprotein into virions.

Elena Sokolskaja1, Silvia Olivari, Madeleine Zufferey, Caterina Strambio-De-Castillia, Massimo Pizzato, Jeremy Luban.   

Abstract

Cyclosporine (CsA) decreases HIV-1 infectivity by blocking HIV-1 capsid (CA) interaction with target cell cyclophilin A (CypA). Yet, HIV-1 virions produced in the presence of CsA also exhibit decreased infectivity that was previously shown to be independent of the well-characterized HIV-1 CA-CypA interaction. Here, we demonstrate that CsA decreases gp120 and gp41 incorporation into HIV-1 virions and that the fusion of these virions with susceptible target cells is impaired. This effect was not observed with HIV-1 virions pseudotyped with the vesicular stomatitis virus glycoprotein or with the amphotropic envelope protein of murine leukemia virus. It was independent of calcineurin signaling, the endoplasmic reticulum luminal protein cyclophilin B, and the long cytoplasmic tail of gp41. Thus, cyclosporine blocks HIV-1 infectivity via two independent mechanisms, the first involving HIV-1 CA in target cells and the second involving HIV-1 Env in producer cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20181694      PMCID: PMC2863729          DOI: 10.1128/JVI.01699-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virions.

Authors:  Sandra Lopez-Vergès; Grégory Camus; Guillaume Blot; Roxane Beauvoir; Richard Benarous; Clarisse Berlioz-Torrent
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-26       Impact factor: 11.205

2.  Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells.

Authors:  Theodora Hatziioannou; David Perez-Caballero; Simone Cowan; Paul D Bieniasz
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants.

Authors:  Abdul A Waheed; Sherimay D Ablan; Marie K Mankowski; James E Cummins; Roger G Ptak; Carl P Schaffner; Eric O Freed
Journal:  J Biol Chem       Date:  2006-08-01       Impact factor: 5.157

4.  Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells.

Authors:  Elena Sokolskaja; Lionel Berthoux; Jeremy Luban
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

5.  The impact of envelope glycoprotein cleavage on the antigenicity, infectivity, and neutralization sensitivity of Env-pseudotyped human immunodeficiency virus type 1 particles.

Authors:  Carolina Herrera; Per Johan Klasse; Elizabeth Michael; Shivani Kake; Kelly Barnes; Christopher W Kibler; Lila Campbell-Gardener; Zhihai Si; Joseph Sodroski; John P Moore; Simon Beddows
Journal:  Virology       Date:  2005-07-20       Impact factor: 3.616

6.  ATPgammaS disrupts human immunodeficiency virus type 1 virion core integrity.

Authors:  Cagan Gurer; Anders Höglund; Stefan Höglund; Jeremy Luban
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses.

Authors:  D Braaten; E K Franke; J Luban
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

8.  Processing, stability, and receptor binding properties of oligomeric envelope glycoprotein from a primary HIV-1 isolate.

Authors:  I Staropoli; C Chanel; M Girard; R Altmeyer
Journal:  J Biol Chem       Date:  2000-11-10       Impact factor: 5.157

9.  Sanglifehrins A, B, C and D, novel cyclophilin-binding compounds isolated from Streptomyces sp. A92-308110. II. Structure elucidation, stereochemistry and physico-chemical properties.

Authors:  T Fehr; J Kallen; L Oberer; J J Sanglier; W Schilling
Journal:  J Antibiot (Tokyo)       Date:  1999-05       Impact factor: 2.649

10.  Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity.

Authors:  Elena Sokolskaja; David M Sayah; Jeremy Luban
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

View more
  8 in total

Review 1.  Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.

Authors:  Maxime J Jean; Guillaume Fiches; Tsuyoshi Hayashi; Jian Zhu
Journal:  AIDS Res Hum Retroviruses       Date:  2018-12-12       Impact factor: 2.205

2.  Mitochondrial glutaminase release contributes to glutamate-mediated neurotoxicity during human immunodeficiency virus-1 infection.

Authors:  Changhai Tian; Lijun Sun; Beibei Jia; Kangmu Ma; Norman Curthoys; Jianqing Ding; Jialin Zheng
Journal:  J Neuroimmune Pharmacol       Date:  2012-04-18       Impact factor: 4.147

Review 3.  Outcomes and management of viral hepatitis and human immunodeficiency virus co-infection in liver transplantation.

Authors:  Stephen E Congly; Karen E Doucette; Carla S Coffin
Journal:  World J Gastroenterol       Date:  2014-01-14       Impact factor: 5.742

4.  CD8(+) Lymphocytes Are Required for Maintaining Viral Suppression in SIV-Infected Macaques Treated with Short-Term Antiretroviral Therapy.

Authors:  Emily K Cartwright; Lori Spicer; S Abigail Smith; David Lee; Randy Fast; Sara Paganini; Benton O Lawson; Melon Nega; Kirk Easley; Joern E Schmitz; Steven E Bosinger; Mirko Paiardini; Ann Chahroudi; Thomas H Vanderford; Jacob D Estes; Jeffrey D Lifson; Cynthia A Derdeyn; Guido Silvestri
Journal:  Immunity       Date:  2016-09-20       Impact factor: 31.745

5.  Host cell species-specific effect of cyclosporine A on simian immunodeficiency virus replication.

Authors:  Hiroaki Takeuchi; Hiroshi Ishii; Tetsuya Kuwano; Natsuko Inagaki; Hirofumi Akari; Tetsuro Matano
Journal:  Retrovirology       Date:  2012-01-06       Impact factor: 4.602

6.  Cyclosporin A inhibits the influenza virus replication through cyclophilin A-dependent and -independent pathways.

Authors:  Xiaoling Liu; Zhendong Zhao; Zheng Li; Chongfeng Xu; Lei Sun; Jilong Chen; Wenjun Liu
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

Review 7.  Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?

Authors:  Christian A Devaux; Cléa Melenotte; Marie-Dominique Piercecchi-Marti; Clémence Delteil; Didier Raoult
Journal:  Front Med (Lausanne)       Date:  2021-09-06

Review 8.  Proteostasis in Viral Infection: Unfolding the Complex Virus-Chaperone Interplay.

Authors:  Ranen Aviner; Judith Frydman
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-03-02       Impact factor: 10.005

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.